Current Report Filing (8-k)
December 07 2016 - 4:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: December 1, 2016
(Date of earliest event reported)
Arcadia
Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37383
|
|
81-0571538
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
202 Cousteau Place, Suite 105
Davis, CA 95618
(Address
of principal executive offices, including zip code)
(530) 756-7077
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On December 1, 2016, Arcadia Biosciences, Inc. (the Company) notified Wendy Neal, the Companys Vice President, Chief Legal Officer and
Secretary, that her employment with the Company will terminate effective February 3, 2017. Ms. Neals departure is a part of the Companys efforts to reduce operating expenses by 15-20%, as discussed on November 10, 2016
during the earnings report conference call for the Companys fiscal quarter ended September 30, 2016. Ms. Neals termination is a termination without cause pursuant to Section 3(a) of the Severance and Change in Control
Agreement between the Company and Ms. Neal, dated May 11, 2015.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ARCADIA BIOSCIENCES, INC.
|
|
|
|
|
Date: December 7, 2016
|
|
|
|
By:
|
|
/s/ Matthew T. Plavan
|
|
|
|
|
Name: Matthew T. Plavan
|
|
|
|
|
Title: Chief Financial Officer
|
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Apr 2023 to Apr 2024